- Home
- GELS vs EDSA Comparison
GELS vs EDSA Comparison
Compare GELS & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GELS
- EDSA
- Stock Information
- Founded
- GELS 2018
- EDSA 2015
- Country
- GELS Australia
- EDSA Canada
- Employees
- GELS N/A
- EDSA N/A
- Industry
- GELS
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- GELS
- EDSA Health Care
- Exchange
- GELS NYSE
- EDSA Nasdaq
- Market Cap
- GELS 15.9M
- EDSA 13.8M
- IPO Year
- GELS 2024
- EDSA N/A
- Fundamental
- Price
- GELS $1.88
- EDSA $2.05
- Analyst Decision
- GELS
- EDSA Strong Buy
- Analyst Count
- GELS 0
- EDSA 2
- Target Price
- GELS N/A
- EDSA $13.00
- AVG Volume (30 Days)
- GELS 4.0M
- EDSA 33.4K
- Earning Date
- GELS 02-15-2025
- EDSA 08-08-2025
- Dividend Yield
- GELS N/A
- EDSA N/A
- EPS Growth
- GELS N/A
- EDSA N/A
- EPS
- GELS N/A
- EDSA N/A
- Revenue
- GELS $95,618.00
- EDSA N/A
- Revenue This Year
- GELS N/A
- EDSA N/A
- Revenue Next Year
- GELS N/A
- EDSA N/A
- P/E Ratio
- GELS N/A
- EDSA N/A
- Revenue Growth
- GELS N/A
- EDSA N/A
- 52 Week Low
- GELS $0.77
- EDSA $1.55
- 52 Week High
- GELS $5.50
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- GELS N/A
- EDSA 52.89
- Support Level
- GELS N/A
- EDSA $1.91
- Resistance Level
- GELS N/A
- EDSA $2.14
- Average True Range (ATR)
- GELS 0.00
- EDSA 0.12
- MACD
- GELS 0.00
- EDSA 0.02
- Stochastic Oscillator
- GELS 0.00
- EDSA 64.52
About GELS GELTEQ LIMITED
Gelteq Ltd is a clinical and science-based company that is focused on developing and commercializing white-label gel-based delivery solutions to preserve the simplicity, accessibility and efficacy of oral delivery without the impediments traditionally associated with other oral delivery methods, with prescription drugs, nutraceuticals, pet care, and other products. It is engaged in the development and testing of a gel-based delivery system for humans and pets. Its principal products are edible gels.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.